Imaging bacterial infections using a radioactive tracer
Official title: [18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
Run by University of Pennsylvania · NCT04263792 · Data updated 2026-11-12
This study is testing a new radioactive tracer to see if it can help doctors find and understand bacterial infections in people who already have them.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | University of Pennsylvania Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Status | Recruiting |
| Started | February 7, 2020 |
| Main results expected | September 2027 |
| Study ends | September 2027 |
| Registry record updated | September 8, 2026 |
| Trial ID | NCT04263792 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with known or suspected bacterial infections.
✕Probably not a fit
Patients currently on antibiotic therapy with trimethoprim or those unable to tolerate imaging procedures may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the biodistribution and kinetics of a radioactive tracer called [18F]fluoropropyl-trimethoprim in human subjects. Participants with known or suspected bacterial infections will receive the tracer, which will be visualized using Positron Emission Tomography/Computed Tomography (PET/CT) imaging. The goal is to understand how the tracer accumulates in areas of active infection, which may improve diagnostic capabilities for bacterial infections. The study is interventional and is currently in Phase 1.
Why it matters
Potential benefit: If successful, this study could enhance the diagnosis and management of bacterial infections, leading to more targeted treatments.
How similar studies have gone: While this approach is novel in the context of using [18F]F-TMP for imaging bacterial infections, similar imaging techniques have shown promise in other studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * At least 18 years of age * Known or suspected bacterial infection, per clinical documentation of suspected infection (e.g. lab results, pathology results, physician progress notes, clinical symptoms of infection) * Able to understand the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures Exclusion Criteria: * Antibiotic therapy with trimethoprim within 48h of the baseline PET/CT scan * Inability to tolerate imaging procedures, in the opinion of an investigator or treating physician * Unstable or other severe medical or psychological comorbidities that would compromise the subject's safety or successful participation in the study, in the opinion of an investigator or treating physician * Pregnant or breast feeding patients; a urine pregnancy test will be performed in women of child-bearing potential prior to \[18F\]F-TMP injection, to confirm non-pregnant status
Where it's running
-
University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Daniel Pryma, MD — University of Pennsylvania
- Study coordinator: Erin Schubert
- Email: erinschu@pennmedicine.upenn.edu
- Phone: 215-662-3041
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CTX-187 first-in-human test in healthy people and people with chronic bronchiectasis and Pseudomonas infection
This study tests CTX-187 to see if it is safe and tolerable when given as IV infusions to healthy adults and adults with chronic bronchiectasis and Pseudomonas aeruginosa infection.
-
Personalized beta-lactam dosing in cirrhosis patients with bacterial infections
This study tests whether tailoring beta-lactam dosing based on patient liver disease and drug levels can help people with cirrhosis and bacterial infections.
-
Vaginitis Diagnostic Algorithm Pilot Using Nanopath and Other Tests
This study tests a new Nanopath vaginal test to see if it correctly detects vaginitis-causing pathogens in up to 1,000 people with vaginitis symptoms.
-
Testing single and multiple IV doses of JKN2501 in healthy Chinese adults
This test gives single and multiple intravenous doses of JKN2501 to healthy Chinese adults to see if it's safe and how the body processes it.
-
Tracking acute treatment and long-term outcomes in children with meningitis
This registry will collect care and outcome information to see how current treatments affect short- and long-term outcomes in children under 18 with suspected meningitis in Brazil.
-
Single antibiotic versus two antibiotics for Pseudomonas bone infection
This study will test whether one antibiotic works as well as two for adults with bone infections caused by Pseudomonas aeruginosa.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.